Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by the presence of neurofibrillary tangles of hyperphosphorylated, aggregated tau protein and extracellular deposits of β‐amyloid peptide. Increased β‐amyloid levels are thought to precede tangle formation, but tau pathology is more closely related to neuronal death. Minocycline, a tetracycline derivative, has potent antiinflammatory, antiapoptotic, and neuroprotective effects in several models of neurodegenerative disease, including models of AD with amyloid pathology. We have used both in vitro and in vivo models of AD to determine whether minocycline may have therapeutic efficacy against tau pathology. In primary cortical neurons, minocycline prevents β‐amyloid‐induced neuronal death, reduces caspase‐3 activation, and lowers generation of caspase‐3‐cleaved tau fragments. Treatment of tangle‐forming transgenic mice (htau line) with minocycline results in reduced levels of tau phosphorylation and insoluble tau aggregates. The in vivo effects of minocycline are also associated with reduced caspase‐3 activation and lowered tau cleavage by caspase‐3. In tau mice, we find that conformational changes in tau are susceptible to minocycline treatment, but are not directly associated with the amount of tau fragments produced, highlighting a dissociation between the development of these pathological tau species. These results suggest a possible novel therapeutic role for minocycline in the treatment of AD and related tauopathies.— Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D. P., Anderton, B. H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739–750 (2009)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In AD, abnormal tau phosphorylation and/or processing are thought to occur as a result of elevated brain A (1).”
BackgroundSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 1×
“Minocycline readily crosses the blood-brain barrier and effectively delays disease progression and reduces neuronal death in mouse models of amyotrophic lateral sclerosis (15), Huntington’s disease (16), and Parkinson’s disease (17).”
BackgroundTikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 1×
“mice (36), we next examined whether minocycline”
Self-citationCaspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543 · cited 7×
“A activates caspase-3, which cleaves tau at aspartate (D) 451 to generate fragments with proapoptotic properties in vitro (12, 13), with tau cleavage thought to precede its hyperphosphorylation (11, 14).”
BackgroundInfluentialCell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms
Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511 · cited 1×
“While the presence and density of NFTs correlates with cognitive decline in AD (2, 3), recent evidence indicates that NFTs are not neurotoxic, but that an earlier, abnormal tau species induces neurodegeneration (4, 5).”
BackgroundConformational change as one of the earliest alterations of tau in Alzheimer's disease
Weaver, C. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00157-3 · Cited by 310 · cited 1×
“place at an early stage in AD, preceding NFT formation, and may represent a more disease-specific alteration than phosphorylation (37, 38).”
Background
Cited by
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Self-citationRegulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639
“This is consistent with several other recent observations in the hTau mice (Kelleher et al., 2007; Noble et al., 2009) as well as other mouse model of tauopathies (Kitazawa et al.”
Favaloro, B., Allocati, N., Graziano, V., Di Ilio, C., & De Laurenzi, V. (2012) · Aging · doi:10.18632/aging.100459 · Cited by 585
Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease
Newcombe, E. A., Camats-Perna, J., Silva, M. L., Valmas, N., Huat, T. J., & Medeiros, R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1313-3 · Cited by 532
Metadata
- Authors
- Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D. P., & Anderton, B. H.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2008-11-11
- Volume
- 23
- Issue
- 3
- Pages
- 739-750
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2083237411
- Cited by
- 130
- References
- 14
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. https://app.cochat.ai/papers/10.1096/fj.08-113795
- The paper
- Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D. P., & Anderton, B. H. (2009). Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. The FASEB Journal. https://doi.org/10.1096/fj.08-113795
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.